```text
Wiki Article
Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also 143653-53-6 identified as C7E3 or bearing the CAS number 143653-53-6, represents a valuable research substance extensively used in thrombosis studies . This antibody fragment selectively targets the glycoprotein IIb/IIIa complex on thrombocytes , blocking thrombus development. Therefore , it's frequently applied as a technique to examine the mechanisms underlying clotting and to assess the efficacy of antiplatelet medications . Availability is typically controlled to institutional settings.
```
Abciximab Research: Utilizing C7E3 and Compound 143653-53-6 in Studies
Ongoing research into abciximab, a antiplatelet agent, frequently utilizes the monoclonal protein C7E3 and the molecule identified as 143653-53-6. These reagents are instrumental for analyzing abciximab's mechanism of action, determining its therapeutic effect in various clinical settings, and exploring potential indicators of patient outcome. Further study leveraging these precise reagents is expected to generate valuable insights for enhancing patient care concerning cardiovascular disease.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role of platelet activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Exploring Research Possibilities with Abciximab 143653-53-6 and C7E3
Recent work suggest that this antiplatelet agent (identified as 143653-53-6) holds significant research potential, particularly when paired with a C7E3 construct. Preliminary reports suggested that this association might improve clinical outcomes in various cardiovascular settings. Further exploration is directed on elucidating the specific mechanism of action between Abciximab and C7E3, involving analysis of thrombocyte cohesion and vascular protection.
- Future investigation work seek to refine administration approaches.
- Animal models are were utilized to more confirm the hypotheses.
- Human studies are necessary to completely determine clinical benefit.
```
Abciximab (C7E3) for Research: Specifications and Characteristics (143653-53-6)
Researchers seeking C7E3 for laboratory studies should carefully consider purity and precise parameters . Material 143653-53-6 is typically offered as a solid powder and thorough analytical documentation including assessment by HPLC , binding affinity assays, and endotoxin testing are available. Verify the source’s documentation clearly states acceptable values for impurities and conforms to established QC criteria .
Pharmaceutical-Grade Abciximab Details & Availability
Acquiring laboratory-grade Abciximab, specifically referencing the compound C7E3 and identified by the catalog number 143653-53-6, requires detailed consideration of its manufacturer. This agent is widely utilized in laboratory studies , particularly those involving platelet adhesion and occlusion. Existing sources offer this substance in varying amounts , typically ranging from milligram to significant bulk amounts . Please recommend reviewing the report of quality to verify quality and appropriateness for your specific purpose. Moreover, check the stability date before obtaining to maintain maximum performance .
- Typical Purity: >95%
- Keeping Conditions: -20°C and suitable conditions
- Application : Platelet Clumping Suppression Studies